CSNK2B: A Potential Drug Target and Biomarker for Cancer (G1460)

Target Name: CSNK2B

NCBI ID: G1460

CSNK2B

CSNK2B: A Potential Drug Target and Biomarker for Cancer

Introduction

CSNK2B (Casein Kinase 2, Beta Polypeptide) is a non-profit protein that plays a crucial role in cell signaling pathways, particularly in the regulation of cell growth, apoptosis, and inflammation. CSNK2B has been identified as a potential drug target and biomarker for cancer due to its unique mechanism of action and its involvement in various cellular processes that are implicated in cancer development.

Synthesis and Expression

CSNK2B is a 21-kDa protein that consists of 21 amino acid residues. It is expressed in various tissues, including liver, lung, heart, kidney, and brain, and is predominantly localized to the cytoplasm. CSNK2B has been shown to have a unique post-translational modification profile, with the majority of residues being modified by phosphorylation.

Function and Interaction

CSNK2B is a protein that is involved in various cellular signaling pathways, including the regulation of cell growth, apoptosis, and inflammation. It plays a critical role in the regulation of cell cycle progression by preventing the inhibition of the G1-cell cycle by factors such as GDP/GTP binding proteins. CSNK2B is also involved in the regulation of cell apoptosis, which is a critical checkpoint mechanism for the termination of cell life.

CSNK2B has been shown to interact with numerous protein partners, including c-Myc, p53, and NF-kappa-B. These interactions have been implicated in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation.

Drug Interaction and Therapeutic Potential

The therapeutic potential of CSNK2B as a drug target is based on its involvement in various cellular processes that are implicated in cancer development. Several studies have shown that CSNK2B is involved in the regulation of cancer cell growth, apoptosis, and angiogenesis.

One of the main drug targets for CSNK2B is the inhibition of its activity, which can be achieved by small molecules, peptides, or antibodies. The most promising small molecules for the inhibition of CSNK2B include PDGF-BB, a growth factor that can induce the expression of CSNK2B, and U0126, an inhibitor of the PI3K/Akt signaling pathway, which is involved in the regulation of cell growth and apoptosis.

Another approach to targeting CSNK2B is the use of antibodies that specifically recognize and target its alpha-helices. The use of antibodies against CSNK2B has shown promise in preclinical studies for the targeting of CSNK2B in cancer cells.

Biomarker Potential

The potential use of CSNK2B as a biomarker for cancer has also been shown. Several studies have shown that the expression of CSNK2B is significantly increased in various types of cancer, including breast, lung, and ovarian cancer. Additionally, the levels of CSNK2B have been shown to be correlated with the clinical outcomes of cancer patients, including response to chemotherapy and overall survival.

Conclusion

In conclusion, CSNK2B is a protein that is involved in various cellular signaling pathways and has been identified as a potential drug target and biomarker for cancer. The inhibition of CSNK2B activity has shown promise in preclinical studies and clinical trials, and its potential as a drug target and biomarker makes it an attractive target for cancer researchers and clinicians. Further studies are needed to fully understand the role of CSNK2B in cancer development and to develop safe and effective therapies that target this protein.

Protein Name: Casein Kinase 2 Beta

Functions: Regulatory subunit of casein kinase II/CK2. As part of the kinase complex regulates the basal catalytic activity of the alpha subunit a constitutively active serine/threonine-protein kinase that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine (PubMed:11239457, PubMed:16818610). Participates in Wnt signaling (By similarity)

The "CSNK2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CSNK2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets